Investment Thesis
Exozymes is a pre-commercial biotech company burning $1.5M annually with only $70.1K in revenue and $1.4M cash, providing approximately 11 months of operational runway before requiring capital raises. The company exhibits severe cash burn relative to assets and no visible path to profitability, making imminent shareholder dilution from equity financing highly likely.
Strengths
- Zero debt burden eliminates leverage risk and preserves financial flexibility
- Liquid asset position of $1.4M provides near-term operational cushion
- Active insider participation with 6 Form 4 filings in 90 days indicates management engagement
Risks
- Critical cash runway of ~11 months at current $1.5M annual operating burn rate creates imminent capital requirement
- Pre-commercial status with only $70.1K revenue shows no meaningful market traction or commercialization progress
- Inevitable equity capital raises will cause substantial shareholder dilution; negative ROE (-155.1%) and ROA (-59.0%) destroy shareholder value
Key Metrics to Watch
- Quarterly cash burn rate and remaining months of runway
- Revenue growth, product commercialization traction, and path to profitability
- Capital raising activity, dilution from future equity issuance, and clinical/regulatory trial progress
Financial Metrics
Revenue
70.1K
Net Income
-2.4M
EPS (Diluted)
$-0.28
Free Cash Flow
-1.6M
Total Assets
4.0M
Cash
1.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-3,406.6%
Net Margin
-3,382.7%
ROE
-155.1%
ROA
-59.0%
FCF Margin
-2,257.8%
Balance Sheet & Liquidity
Current Ratio
1.32x
Quick Ratio
1.32x
Debt/Equity
0.00x
Debt/Assets
62.0%
Interest Coverage
-32.07x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T07:43:13.886504 |
Data as of: 2026-03-31 |
Powered by Claude AI